In correlation with DYRKs expressions in CRC subtypes, DYRK1A and 3 significantly correlated with tumor infiltrating immune cells; this suggests that those two kinases can act as a prognostic marker for MSI and immunotherapy response. Here, DYRK1A is linked to neoplasm.